Adcetris
Takeda’s Adcetris secures expanded approval in Europe for untreated CD30+ Stage IV Hodgkin lymphoma
February 14, 2019Sales and Marketing Adcetris, Cancer, Europe, Hodgkin lymphoma, Takeda, pharma
Takeda’s Adcetris (brentuximab vedotin) has seen its marketing authorisation expanded by the European Commission to include the treatment of previously …
Old CDF drug not recommended in initial NICE guidance due to lack of evidence
August 10, 2016Research and Development, Sales and Marketing Adcetris, Cancer Drugs Fund, NICE, Takeda, hodgkin's lymphoma
The National Institute for Health and Care Excellence (NICE) has published draft guidance not recommending Takeda’s Adectris (brentuximab vedotin), despite …
Phase III success for Takeda in lymphoma drug
August 1, 2016Manufacturing and Production, Research and Development Adcetris, Seattle Genetics, Takeda, lymphoma
Takeda Oncology and Seattle Generic have announced new Phase III data for trial drug, Adcetris (brentuximab vedotin), in patients with …
Takeda eyes new drug licences following positive blood cancer studies
December 11, 2014Research and Development, Sales and Marketing Adcetris, Takeda, Velcade, ash, bortezomib, brentuximab vedotin, hematology
Takeda is bringing its biotech arm in-house to create a global oncology business unit, which it says will drive forward …
Blood cancer drug Adcetris approved by FDA
August 24, 2011Sales and Marketing Adcetris, Cancer, Seattle Genetics, lymphoma
The FDA has approved Seattle Genetics’ blood cancer drug Adcetris for two forms of lymphoma. Adcetris (brentuximab vedotin) can now …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
